Organic-Vaccines, a company specializing in using biotechnology to utilize a patient’s own cells for treatments, recently applied to the World Health Organization (WHO) for compassionate use of the company’s MERS-CoV (Middle-East Respiratory Syndrome Coronavirus) vaccine.
The first confirmed cases of MERS-CoV occurred in Saudi Arabia in 2012. Since then, 804 cases have been reported in the country with 43 percent of patients dying as of Thursday. Worldwide, WHO has reported 887 cases of MERS-CoV as of Oct. 16.
Organic-Vaccines is preparing its vaccine in order to respond rapidly to future MERS-CoV cases. Early preparation is key to protecting health professionals, first responders and citizens, as well as preventing worldwide pandemics.
Organic-Vaccines wants to fully develop its MERS-CoV vaccine before the spring. Camels, which most health professionals agree are MERS carriers, give birth in the spring. Finalizing the vaccine before the newborns arrive may be key to preventing more MERS-CoV cases.
The company’s researchers are confident that they will receive support from Saudi Arabia's Ministry of Health, which will hasten the company’s progress in developing the vaccine.
In Queensland, Australia, another company’s vaccine, which had antibodies similar to Organic-Vaccine’s vaccine, was given to humans who had contracted Nipah and Hendra viruses. The patients did not experience any side effects.